Ibrahim Bayram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ibrahim Bayram has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Gülay Sezgin
ÇUKUROVA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ÇOCUK SAĞLIĞI VE HASTALIKLARI ANABİLİM DALI, ONKOLOJİ BİLİM DALI
11 shared publications - Serhan Küpeli
ÇUKUROVA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ÇOCUK SAĞLIĞI VE HASTALIKLARI ANABİLİM DALI, ONKOLOJİ BİLİM DALI
11 shared publications - Ayşe Özkan
Department of Pediatric Hematology-Oncology, Faculty of Medicine, Çukurova University, Adana, Türkiye
9 shared publications - Atila Tanyeli
ÇUKUROVA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ÇOCUK SAĞLIĞI VE HASTALIKLARI ANABİLİM DALI, ONKOLOJİ BİLİM DALI
5 shared publications - Ahmet Yöntem
Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
2 shared publications - Begül Yağcı-Küpeli
Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr
2 shared publications
Latest Publications
- Open Access
- 30 June 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (2) , 506-518
Improved outcomes in children with acute lymphoblastic leukemia treated with modified BFM protocols: a single-center experience
Purpose: We compared the treatment protocols used for acute lymphoblastic leukemia (ALL) patients admitted to our clinic between January 1990 and September 2021. Materials and Methods: Patient files were retrospectively reviewed. Data collection was finalized in June 2022. Patients were divided into three groups based on treatment protocols. Group I (n=234) received BFM-85, -90, or -95 protocols between 1990 and January 2001. Group II (n=139) received a modified BFM-95 protocol (TRALL-2000) between January 2001 and March 2007. Group III (n=199) received a center-modified TRALL-2000 protocol starting in 2007. Results: Of the patients, 344 (60.1%) were boys and 228 (39.9%) were girls. The 10-year overall survival (OS) rates were 30%, 53%, and 73% for Groups I, II, and III, respectively. Event-free survival (EFS) rates were 27%, 40%, and 64%. In Group III, the 10-year OS was 92% for the standard-risk group (SRG), 71% for the medium-risk group (MRG), and 59% for the high-risk group (HRG); the corresponding EFS rates were 72%, 68%, and 49%. Among Group III patients, the 10-year OS was 64% for girls and 78% for boys. The OS for B-cell ALL was 71%, and for T-cell ALL, 78%. Conclusion: OS and EFS rates in Group III were significantly higher than in earlier groups. Contrary to existing literature, T-cell ALL patients and male patients in Group III had superior outcomes compared to B-cell ALL patients and female patients.
- 30 June 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (2) , 506-518
Open AccessImproved outcomes in children with acute lymphoblastic leukemia treated with modified BFM protocols: a single-center experience
Purpose: We compared the treatment protocols used for acute lymphoblastic leukemia (ALL) patients admitted to our clinic between January 1990 and September 2021. Materials and Methods: Patient files were retrospectively reviewed. Data collection was finalized in June 2022. Patients were divided into three groups based on treatment protocols. Group I (n=234) received BFM-85, -90, or -95 protocols between 1990 and January 2001. Group II (n=139) received a modified BFM-95 protocol (TRALL-2000) between January 2001 and March 2007. Group III (n=199) received a center-modified TRALL-2000 protocol starting in 2007. Results: Of the patients, 344 (60.1%) were boys and 228 (39.9%) were girls. The 10-year overall survival (OS) rates were 30%, 53%, and 73% for Groups I, II, and III, respectively. Event-free survival (EFS) rates were 27%, 40%, and 64%. In Group III, the 10-year OS was 92% for the standard-risk group (SRG), 71% for the medium-risk group (MRG), and 59% for the high-risk group (HRG); the corresponding EFS rates were 72%, 68%, and 49%. Among Group III patients, the 10-year OS was 64% for girls and 78% for boys. The OS for B-cell ALL was 71%, and for T-cell ALL, 78%. Conclusion: OS and EFS rates in Group III were significantly higher than in earlier groups. Contrary to existing literature, T-cell ALL patients and male patients in Group III had superior outcomes compared to B-cell ALL patients and female patients.
- Open Access
- 31 March 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (1) , 83-89
Assessment of respiratory functions in pediatric oncology patients receiving bleomycin treatment
Purpose: Bleomycin is a chemotherapeutic agent that causes lung toxicity. Bleomycin is mostly used in the treatment of germ cell tumors (GCT) and Hodgkin Lymphoma (HL) in childhood cancers. In this study, we aimed to detect bleomycin toxicity to the lung in the early period. Materials and Methods: Pulmonary functions of patients aged 5 years and older who were admitted to the Division of Pediatric Oncology with GCT and HL between 2012 and 2022, who received bleomycin treatment and were in remission for at least 6 months were evaluated. The evaluation of respiratory functions was based on history, physical examination, posteroanterior chest radiography (chest X-ray) and pulmonary function test (PFT). Results: The number of patients with GCT who entered follow-up and lived were 59, those with HL were 89. The number of patients who received bleomycin treatment, were in remission for at least 6 months, could be reached and underwent PFT were 46 for HL and 12 for GCT. There were 21 patients with PFT abnormalities. Of these patients, 3 were diagnosed with GCT and 18 were diagnosed with HL. The type of PFT abnormality in the majority of patients was restrictive disorder. Conclusion: The absence of respiratory symptoms in 90% of patients with PFT abnormalities shows the importance of PFT in asymptomatic patients. Patients who have received bleomycin as part of treatment should also be followed-up for late pulmonary toxicity.
- 31 March 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (1) , 83-89
Open AccessAssessment of respiratory functions in pediatric oncology patients receiving bleomycin treatment
Purpose: Bleomycin is a chemotherapeutic agent that causes lung toxicity. Bleomycin is mostly used in the treatment of germ cell tumors (GCT) and Hodgkin Lymphoma (HL) in childhood cancers. In this study, we aimed to detect bleomycin toxicity to the lung in the early period. Materials and Methods: Pulmonary functions of patients aged 5 years and older who were admitted to the Division of Pediatric Oncology with GCT and HL between 2012 and 2022, who received bleomycin treatment and were in remission for at least 6 months were evaluated. The evaluation of respiratory functions was based on history, physical examination, posteroanterior chest radiography (chest X-ray) and pulmonary function test (PFT). Results: The number of patients with GCT who entered follow-up and lived were 59, those with HL were 89. The number of patients who received bleomycin treatment, were in remission for at least 6 months, could be reached and underwent PFT were 46 for HL and 12 for GCT. There were 21 patients with PFT abnormalities. Of these patients, 3 were diagnosed with GCT and 18 were diagnosed with HL. The type of PFT abnormality in the majority of patients was restrictive disorder. Conclusion: The absence of respiratory symptoms in 90% of patients with PFT abnormalities shows the importance of PFT in asymptomatic patients. Patients who have received bleomycin as part of treatment should also be followed-up for late pulmonary toxicity.
- 13 March 2024
- Published by Springer Nature in Child's Nervous System
- Vol. 40 (6) , 1671-1680
Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma
Purpose Pediatric diffuse intrinsic pontine glioma (DIPG) is a fatal disease associated with a median survival of < 1 year despite aggressive treatments. This retrospective study analyzed the treatment outcomes of patients aged < 18 years who were diagnosed with DIPG between 2012 and 2022 and who received different chemotherapy regimens. Methods After radiotherapy, patients with DIPG received nimotuzumab-vinorelbine combination or temozolomide-containing therapy. When nimotuzumab was unavailable, it was replaced by vincristine, etoposide, and carboplatin/cyclophosphamide (VECC). Temozolomide was administered as a single agent or a part of the combination chemotherapy comprising temozolomide, irinotecan, and bevacizumab. Furthermore, 1- and 3-year overall survival (OS), progression-free survival (PFS), and median OS and PFS were analyzed. Results The median age of 40 patients with DIPG was 97 ± 46.93 (23–213) months; the median follow-up time was 12 months. One and 3-year OS were 35.0% and 7.5%, respectively. Median OS was 12 months in all patients (n = 40), and it was 16, 10, and 11 months in those who received first-line nimotuzumab-vinorelbine combination (n = 13), temozolomide-based (n = 14), and VECC (n = 6) chemotherapy regimens, respectively (p = 0.360). One patient who received gefitinib survived for 16 months. Conversely, patients who never received radiotherapy and any antineoplastic medicamentous therapy (n = 6) had a median OS of 4 months. Conclusion Nimotuzumab-vinorelbine combination therapy prolonged OS by 6 months compared with temozolomide-containing chemotherapy, although the difference was not statistically significant.
- 13 March 2024
- Published by Springer Nature in Child's Nervous System
- Vol. 40 (6) , 1671-1680
Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma
Purpose Pediatric diffuse intrinsic pontine glioma (DIPG) is a fatal disease associated with a median survival of < 1 year despite aggressive treatments. This retrospective study analyzed the treatment outcomes of patients aged < 18 years who were diagnosed with DIPG between 2012 and 2022 and who received different chemotherapy regimens. Methods After radiotherapy, patients with DIPG received nimotuzumab-vinorelbine combination or temozolomide-containing therapy. When nimotuzumab was unavailable, it was replaced by vincristine, etoposide, and carboplatin/cyclophosphamide (VECC). Temozolomide was administered as a single agent or a part of the combination chemotherapy comprising temozolomide, irinotecan, and bevacizumab. Furthermore, 1- and 3-year overall survival (OS), progression-free survival (PFS), and median OS and PFS were analyzed. Results The median age of 40 patients with DIPG was 97 ± 46.93 (23–213) months; the median follow-up time was 12 months. One and 3-year OS were 35.0% and 7.5%, respectively. Median OS was 12 months in all patients (n = 40), and it was 16, 10, and 11 months in those who received first-line nimotuzumab-vinorelbine combination (n = 13), temozolomide-based (n = 14), and VECC (n = 6) chemotherapy regimens, respectively (p = 0.360). One patient who received gefitinib survived for 16 months. Conversely, patients who never received radiotherapy and any antineoplastic medicamentous therapy (n = 6) had a median OS of 4 months. Conclusion Nimotuzumab-vinorelbine combination therapy prolonged OS by 6 months compared with temozolomide-containing chemotherapy, although the difference was not statistically significant.
- 26 January 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14691
Improvement of survival after hematopoietic stem cell transplantation and trends at a pediatric transplantation center; a three‐decade journey
Background: Advances in stem cell transplantation have resulted in improved outcomes.Methods: This is a retrospective study aimed to analyze changes in patient profile, transplantation, graft characteristics, and outcome among 241 pediatric patients who received stem cell transplantation in a single center between 1993 and 2019.Results: In the 2010–2019, compared with the 1993–2009 period, a significantly higher 5‐year overall survival (60% vs. 44%, p = .022) and an event‐free survival (53% vs. 34%, p = .025) were observed. Cumulative incidence of deaths due to relapse or progression between the 1993–2009 and 2010–2019 periods were 33% and 26% respectively (p = .66). Cumulative incidence of non‐relapse mortality was significantly higher during the 1993–2009 period compared with the 2010–2019 period for malignant diseases (57.7% vs. 28.3%, p = .007). The overall survival from acute graft‐versus‐host disease between 1993 and 2009 was 11% versus 46% between 2010 and 2019 (p = .0001). The overall survival from infection in both eras did not show any difference (p = .41).Conclusions: Development in transplantation technology has led to a decrease in non‐relapse mortality and better control of graft‐versus‐host disease. However, relapse and infection remained as major causes of death. Studies evaluating institutional trends in patients undergoing HSCT and analyzing their mortality profile, can improve the management of patients, leading to a reduction in transplant‐related problems.
- 26 January 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14691
Improvement of survival after hematopoietic stem cell transplantation and trends at a pediatric transplantation center; a three‐decade journey
Background: Advances in stem cell transplantation have resulted in improved outcomes.Methods: This is a retrospective study aimed to analyze changes in patient profile, transplantation, graft characteristics, and outcome among 241 pediatric patients who received stem cell transplantation in a single center between 1993 and 2019.Results: In the 2010–2019, compared with the 1993–2009 period, a significantly higher 5‐year overall survival (60% vs. 44%, p = .022) and an event‐free survival (53% vs. 34%, p = .025) were observed. Cumulative incidence of deaths due to relapse or progression between the 1993–2009 and 2010–2019 periods were 33% and 26% respectively (p = .66). Cumulative incidence of non‐relapse mortality was significantly higher during the 1993–2009 period compared with the 2010–2019 period for malignant diseases (57.7% vs. 28.3%, p = .007). The overall survival from acute graft‐versus‐host disease between 1993 and 2009 was 11% versus 46% between 2010 and 2019 (p = .0001). The overall survival from infection in both eras did not show any difference (p = .41).Conclusions: Development in transplantation technology has led to a decrease in non‐relapse mortality and better control of graft‐versus‐host disease. However, relapse and infection remained as major causes of death. Studies evaluating institutional trends in patients undergoing HSCT and analyzing their mortality profile, can improve the management of patients, leading to a reduction in transplant‐related problems.
- Open Access
- 30 June 2023
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 48 (2) , 377-384
DNA polymerase delta (POLD1 and POLD2) gene expression in pediatric acute lymphoblastic leukemia patients and its relationship with prognosis
Purpose: This study aimed to investigate the status of DNA polymerase delta (POLD1 and POLD2) gene expression at the time of diagnosis in pediatric acute lymphoblastic leukemia (ALL) patients, compared with the normal population, and its relationship with prognosis and other clinical findings. Materials and Methods: Seventy-three patients diagnosed with ALL between January 2008 and November 2015 and 29 healthy control subjects were included in the study. Gene expression profiling of peripheral blood samples was performed using Real-time PCR. Results: The mean value of POLD1 gene expression was found to be significantly higher in ALL patients at the time of diagnosis than the control group (376.5± 685.8 and 17.9± 19.8, respectively), but there was no difference in POLD2 gene expression (511.5± 898.1 and 125.4± 132.7, respectively). POLD1 and POLD2 gene expressions were found to be low in patients with relapse and exitus, but the results were not statistically significant. Patients with low levels of POLD1 expression had lower survival rates in the 5th year than those with high levels of expression (54% and 68%, respectively), and similarly, patients with low levels of POLD2 expression had lower survival rates in the 5th year compared to those with high levels of expression (58% and 68%, respectively). Conclusion: Lower POLD1 and POLD2 expressions at the time of diagnosis in ALL patients may adversely affects the prognosis.
- 30 June 2023
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 48 (2) , 377-384
Open AccessDNA polymerase delta (POLD1 and POLD2) gene expression in pediatric acute lymphoblastic leukemia patients and its relationship with prognosis
Purpose: This study aimed to investigate the status of DNA polymerase delta (POLD1 and POLD2) gene expression at the time of diagnosis in pediatric acute lymphoblastic leukemia (ALL) patients, compared with the normal population, and its relationship with prognosis and other clinical findings. Materials and Methods: Seventy-three patients diagnosed with ALL between January 2008 and November 2015 and 29 healthy control subjects were included in the study. Gene expression profiling of peripheral blood samples was performed using Real-time PCR. Results: The mean value of POLD1 gene expression was found to be significantly higher in ALL patients at the time of diagnosis than the control group (376.5± 685.8 and 17.9± 19.8, respectively), but there was no difference in POLD2 gene expression (511.5± 898.1 and 125.4± 132.7, respectively). POLD1 and POLD2 gene expressions were found to be low in patients with relapse and exitus, but the results were not statistically significant. Patients with low levels of POLD1 expression had lower survival rates in the 5th year than those with high levels of expression (54% and 68%, respectively), and similarly, patients with low levels of POLD2 expression had lower survival rates in the 5th year compared to those with high levels of expression (58% and 68%, respectively). Conclusion: Lower POLD1 and POLD2 expressions at the time of diagnosis in ALL patients may adversely affects the prognosis.
- Open Access
- 31 March 2023
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 48 (1) , 64-71
Expression of nuclear pore protein POM121 in childhood acute lymphoblastic leukemias and its relationship with prognosis
Purpose: We aimed to investigate the status of POM121 gene expression, which is one of the nuclear pore proteins in childhood acute lymphoblastic leukemias (ALL), compared with the normal population, and its relationship with prognosis and other clinical findings. Materials and Methods: Fifty-nine patients with ALL followed up and treated between January 2008 and November 2013, and 36 control subjects were included in the study. A real-time PCR method was used to detect POM121 gene expressions. Results: The mean value of POM121 expression was 3.75±2.91 in ALL patients and 3.32±3.76 in the control group. The 3 and 10 year overall survival (OS) was better in ALL with lower POM121 expression (77%, 70% versus 68%, 58%, respectively). Although the OS was better in B-ALL patients, with lower POM121 expression (84%, 75% versus 54%, 46%, respectively), in T-ALL, in contrast, the OS results were better in patients with a higher POM121 expression (90%, 90% versus 60%, 60%, respectively). Patients with a higher POM121 expression than the mean of the control group and who had relapse and central nervous system involvement had statistically significantly lower OS results in the 3rd and 10th years (16%, 0% versus 84%, 78%, respectively). Conclusion: High POM121 expression negatively affects the prognosis in patients with ALL. This is a study to show the relationship between POM121 expression and prognosis in childhood acute lymphoblastic leukemias, POM121 function will be clarified further with more comprehensive studies.
- 31 March 2023
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 48 (1) , 64-71
Open AccessExpression of nuclear pore protein POM121 in childhood acute lymphoblastic leukemias and its relationship with prognosis
Purpose: We aimed to investigate the status of POM121 gene expression, which is one of the nuclear pore proteins in childhood acute lymphoblastic leukemias (ALL), compared with the normal population, and its relationship with prognosis and other clinical findings. Materials and Methods: Fifty-nine patients with ALL followed up and treated between January 2008 and November 2013, and 36 control subjects were included in the study. A real-time PCR method was used to detect POM121 gene expressions. Results: The mean value of POM121 expression was 3.75±2.91 in ALL patients and 3.32±3.76 in the control group. The 3 and 10 year overall survival (OS) was better in ALL with lower POM121 expression (77%, 70% versus 68%, 58%, respectively). Although the OS was better in B-ALL patients, with lower POM121 expression (84%, 75% versus 54%, 46%, respectively), in T-ALL, in contrast, the OS results were better in patients with a higher POM121 expression (90%, 90% versus 60%, 60%, respectively). Patients with a higher POM121 expression than the mean of the control group and who had relapse and central nervous system involvement had statistically significantly lower OS results in the 3rd and 10th years (16%, 0% versus 84%, 78%, respectively). Conclusion: High POM121 expression negatively affects the prognosis in patients with ALL. This is a study to show the relationship between POM121 expression and prognosis in childhood acute lymphoblastic leukemias, POM121 function will be clarified further with more comprehensive studies.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15562
Pediatric posterior reversible encephalopathy syndrome: Age related clinico‐radiological profile and neurologic outcomes
Background: The aim of this study was to analyze the characteristics of pediatric posterior reversible encephalopathy syndrome (PRES) to determine clinical and radiologic differences between younger and older age groups, and to identify risk factors for development of any neurologic sequelae.Methods: The study cohort consisted of confirmed pediatric PRES patients in a tertiary care university hospital from January, 2015, to December, 2020. Demographic and clinical properties, radiological manifestations, and neurologic outcomes were noted. Children aged ≤6 years were compared with those older than 6 years and factors affecting neurologic outcomes were evaluated.Results: The most common underlying diseases were oncological (37%) and kidney diseases (29%). Epileptic seizures were the most frequent symptoms at initial clinical presentation. The regions in the brain that were most commonly involved were the occipital region (n = 65, 96%), the parietal region (n = 52, 77%), and the frontal lobe (n = 35, 54%). Magnetic resonance imaging (MRI) findings were consistent with atypical patterns in most of the study cohort (71%). Patients with unfavorable clinical outcomes (n = 13, 19.1%) had longer initial seizure times and longer encephalopathy times, lower leucocyte and absolute neutrophil counts, and lower neutrophil to lymphocyte ratios. No relationship was found between MRI findings, involvement patterns, and neurologic outcomes.Conclusions: No clinically specific differences between two different age groups were found. Atypical imaging manifestations of pediatric PRES in our study had an incidence that was as high as those found in earlier adult studies. Multivariate logistic regression analysis showed that the initial neutrophil to lymphocyte ratio, absolute neutrophil counts, and white cell counts could not predict poor neurologic outcomes.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15562
Pediatric posterior reversible encephalopathy syndrome: Age related clinico‐radiological profile and neurologic outcomes
Background: The aim of this study was to analyze the characteristics of pediatric posterior reversible encephalopathy syndrome (PRES) to determine clinical and radiologic differences between younger and older age groups, and to identify risk factors for development of any neurologic sequelae.Methods: The study cohort consisted of confirmed pediatric PRES patients in a tertiary care university hospital from January, 2015, to December, 2020. Demographic and clinical properties, radiological manifestations, and neurologic outcomes were noted. Children aged ≤6 years were compared with those older than 6 years and factors affecting neurologic outcomes were evaluated.Results: The most common underlying diseases were oncological (37%) and kidney diseases (29%). Epileptic seizures were the most frequent symptoms at initial clinical presentation. The regions in the brain that were most commonly involved were the occipital region (n = 65, 96%), the parietal region (n = 52, 77%), and the frontal lobe (n = 35, 54%). Magnetic resonance imaging (MRI) findings were consistent with atypical patterns in most of the study cohort (71%). Patients with unfavorable clinical outcomes (n = 13, 19.1%) had longer initial seizure times and longer encephalopathy times, lower leucocyte and absolute neutrophil counts, and lower neutrophil to lymphocyte ratios. No relationship was found between MRI findings, involvement patterns, and neurologic outcomes.Conclusions: No clinically specific differences between two different age groups were found. Atypical imaging manifestations of pediatric PRES in our study had an incidence that was as high as those found in earlier adult studies. Multivariate logistic regression analysis showed that the initial neutrophil to lymphocyte ratio, absolute neutrophil counts, and white cell counts could not predict poor neurologic outcomes.
- Open Access
- 28 December 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (4) , 1578-1583
Çocuklarda Wilms tümörü dışındaki böbrek tümörlerinde risk grubunun sağkalıma etkisi
Purpose: The aim of this study was to evaluate tne effect of the risk group on the clinical features of the disease, treatment strategies and especially survival in children with Non-Wilms’ renal tumors (NWRTs). Materials and Methods: Patients diagnosed with NWRTs followed up and treated between January 2012 and January 2022 were included in the study (n=29; 16 boys and 13 girls). They were categorized into high- and low-risk groups based on their histological type. Patient records were reviewed retrospectively. Clinical characteristics, treatments, and outcomes of these patients were analyzed. Results: The high-risk group comprised clear cell sarcoma (CCSK) (n=8, 27.6%), malignant rhabdoid tumor (MRT) (n=3, 10.3%), renal cell carcinoma (n=2, 6.9%), non-Hodgkin lymphoma (n=1, 3.4%), and primitive neuroectodermal tumor (PNET) (n=1, 4%). The low-risk group comprised congenital mesoblastic nephroma (CMN) (n=9, 31%), angiomyolipoma (n=4, 3.8%), and hemangioma (n=1, 3.4%). Five patients died due to disease progression (mortality rate, 17%), all of whom belonged to the high-risk group (three patients with MRT, one with CCSK, one with PNET). The 5-year survival rate was 72% for the high risk group and 100% for the low risk group. Conclusion: Although low-risk tumors are associated with excellent outcomes, the outcomes vary in high-risk tumors. Physicians should be wary of high mortality rates in children with MRT, CCSK, and PNET, and should design multidisciplinary treatments for NWRTs.
- 28 December 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (4) , 1578-1583
Open AccessÇocuklarda Wilms tümörü dışındaki böbrek tümörlerinde risk grubunun sağkalıma etkisi
Purpose: The aim of this study was to evaluate tne effect of the risk group on the clinical features of the disease, treatment strategies and especially survival in children with Non-Wilms’ renal tumors (NWRTs). Materials and Methods: Patients diagnosed with NWRTs followed up and treated between January 2012 and January 2022 were included in the study (n=29; 16 boys and 13 girls). They were categorized into high- and low-risk groups based on their histological type. Patient records were reviewed retrospectively. Clinical characteristics, treatments, and outcomes of these patients were analyzed. Results: The high-risk group comprised clear cell sarcoma (CCSK) (n=8, 27.6%), malignant rhabdoid tumor (MRT) (n=3, 10.3%), renal cell carcinoma (n=2, 6.9%), non-Hodgkin lymphoma (n=1, 3.4%), and primitive neuroectodermal tumor (PNET) (n=1, 4%). The low-risk group comprised congenital mesoblastic nephroma (CMN) (n=9, 31%), angiomyolipoma (n=4, 3.8%), and hemangioma (n=1, 3.4%). Five patients died due to disease progression (mortality rate, 17%), all of whom belonged to the high-risk group (three patients with MRT, one with CCSK, one with PNET). The 5-year survival rate was 72% for the high risk group and 100% for the low risk group. Conclusion: Although low-risk tumors are associated with excellent outcomes, the outcomes vary in high-risk tumors. Physicians should be wary of high mortality rates in children with MRT, CCSK, and PNET, and should design multidisciplinary treatments for NWRTs.
- Open Access
- 30 June 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (2) , 870-875
Relationship of telomerase activity with prognosis in patients with neuroblastoma
Purpose: The aim of this study was to investigate the effect of telomerase activity on clinical characteristics and survival of patients with neuroblastoma. Materials and Methods: This study was carried out by examining telomerase activity in previously taken pathology preparations of 87 patients who were diagnosed with neuroblastoma between 2011 and 2019 in the Pediatric Oncology Department of Çukurova University Faculty of Medicine. Results: Totally 87 patients, 46 males (52.9%) and 41 females (47.1%), were included in our study. Median age at the time of diagnosis was 3.0 (0.08-15) years. Twenty-three (26.4%) patients included in the study had telomerase activity, 64 (73.6%) had no telomerase activity. Overall survival (OS) of patients with telomerase activity up to 8 years were 84%, while event-free survival (EFS) was 56%. Patients without telomerase activity had a 93% OS for up to 8 years, while EFS was 70%. There was no significant relationship between patients with or without telomerase activity in terms of sex, age, stage, risk group, relapse, myc- n amplification, OS and EFS. Conclusions: In this study, no significant difference was found between telomerase activity and clinical features and survival of neuroblastoma patients. Prospective studies involving larger numbers of patients will more clearly demonstrate the impact of telomerase activity on the prognosis of patients with neuroblastoma.
- 30 June 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (2) , 870-875
Open AccessRelationship of telomerase activity with prognosis in patients with neuroblastoma
Purpose: The aim of this study was to investigate the effect of telomerase activity on clinical characteristics and survival of patients with neuroblastoma. Materials and Methods: This study was carried out by examining telomerase activity in previously taken pathology preparations of 87 patients who were diagnosed with neuroblastoma between 2011 and 2019 in the Pediatric Oncology Department of Çukurova University Faculty of Medicine. Results: Totally 87 patients, 46 males (52.9%) and 41 females (47.1%), were included in our study. Median age at the time of diagnosis was 3.0 (0.08-15) years. Twenty-three (26.4%) patients included in the study had telomerase activity, 64 (73.6%) had no telomerase activity. Overall survival (OS) of patients with telomerase activity up to 8 years were 84%, while event-free survival (EFS) was 56%. Patients without telomerase activity had a 93% OS for up to 8 years, while EFS was 70%. There was no significant relationship between patients with or without telomerase activity in terms of sex, age, stage, risk group, relapse, myc- n amplification, OS and EFS. Conclusions: In this study, no significant difference was found between telomerase activity and clinical features and survival of neuroblastoma patients. Prospective studies involving larger numbers of patients will more clearly demonstrate the impact of telomerase activity on the prognosis of patients with neuroblastoma.
- Open Access
- 1 January 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (2) , 596-602
Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma
Purpose: Some patients with cancer use herbal therapy as an adjunct while receiving conventional cancer treatments. Beta-glucans have direct cytotoxic effects on cancer cells as well as stimulatory effects on the immune system. In this study, a nutritional supplement containing 1,3-1,6 beta-glucan obtained from baker's yeast (Saccharomyces cerevisiae) was used by patients diagnosed with sarcoma, and this study aimed to retrospectively evaluate the effect of beta-glucan use on the incidence of neutropenic fever (NF) and survival rates. Materials and Methods: Among the patients diagnosed with sarcoma between 2014 and 2017, 27 patients who used beta-glucan were included in the beta-glucan group, and 31 patients who did not use beta-glucan were included in the control group. The clinical records of patients were retrospectively analyzed. Results: The number of patients who had NF and the mean length of hospital stay due to NF were higher in the beta-glucan group than those in the control group, but the results were not statistically significant. The overall survival rates at 5 years were 83.3% and 52.9% and event-free survival rates at 5 years were 48.1% and 71% in the beta-glucan and control groups, respectively. Conclusion: The effect of prophylactic beta-glucan use on the incidence of NF and survival rates in pediatric patients with sarcoma should be evaluated more reliably in further prospective studies on a large patient group.
- 1 January 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (2) , 596-602
Open AccessEffect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma
Purpose: Some patients with cancer use herbal therapy as an adjunct while receiving conventional cancer treatments. Beta-glucans have direct cytotoxic effects on cancer cells as well as stimulatory effects on the immune system. In this study, a nutritional supplement containing 1,3-1,6 beta-glucan obtained from baker's yeast (Saccharomyces cerevisiae) was used by patients diagnosed with sarcoma, and this study aimed to retrospectively evaluate the effect of beta-glucan use on the incidence of neutropenic fever (NF) and survival rates. Materials and Methods: Among the patients diagnosed with sarcoma between 2014 and 2017, 27 patients who used beta-glucan were included in the beta-glucan group, and 31 patients who did not use beta-glucan were included in the control group. The clinical records of patients were retrospectively analyzed. Results: The number of patients who had NF and the mean length of hospital stay due to NF were higher in the beta-glucan group than those in the control group, but the results were not statistically significant. The overall survival rates at 5 years were 83.3% and 52.9% and event-free survival rates at 5 years were 48.1% and 71% in the beta-glucan and control groups, respectively. Conclusion: The effect of prophylactic beta-glucan use on the incidence of NF and survival rates in pediatric patients with sarcoma should be evaluated more reliably in further prospective studies on a large patient group.